Outcomes of Kidney Transplant Recipients in the Era of Clone-Directed Therapy: A Case Series (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1014; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Induction immunsuppression is basiliximab or thymoglobulin...One experienced hematologic relapse at 25 months post-KTx, treated with daratumumab followed by venetoclax-based therapy...Intensive monitoring for viral reactivation, secondary malignancies, and hematologic relapse remains essential to improve patient and allograft outcomes. Demographics and Outcomes of KTx Recipients and MM"
Clinical • Hematological Malignancies • Multiple Myeloma • Skin Cancer • Transplantation
|
|
Ratib Talal Mahfouz; Yasin Obeidat; Jason Valent; Richard A. Fatica; Emilio D. Poggio; Jack Khouri; Itunu O. Owoyemi
|